Johnson & Johnson News

Johnson & Johnson is a large and diverse company, so staying up-to-date with developments, company performance, and their plans for the future is not easy. That's why Wiser created the Johnson & Johnson news digest. It is delivered once a day and contains the key articles from around the web in order to keep you informed. Johnson & Johnson is primarily involved in the health sector. Its interests are spread across 275 different companies in 60 countries. It was founded in 1886 and its headquarters is in New Jersey. Worldwide it employs about 128,000 people and its main consumer brands include Band-Aid, Johnson's baby products and Neutrogena. It also has a medical devices and diagnostics sector, and a pharmaceuticals sector. Challenges exist in the later, particularly regarding the competition from generic versions of some of its drugs. Its research and development pipeline is also watched with interest, as is its movements in terms of expansion - further acquisitions, particularly in the medical devices field, are expected. Make sure you do not miss any Johnson & Johnson news, analysis or information by registering for the free Wiser daily email.

Recent Johnson & Johnson News Coverage
 
Your Weekly Recommendations Saturday, September 23, 2017
 
Recommended for you
Johnson & Johnson was alerted to risk of asbestos in talc in ’70s, files show.
Bloomberg • Jef Feeley
Where To Invest Now
Seeking Alpha • Nicholas P. Cheer
3 Things In Biotech You Should Learn Today: September 22, 2017
Seeking Alpha • Zach Hartman
Johnson & Johnson Acquires Sightbox For Contact Lens Subscriptions
Seeking Alpha • Donovan Jones
Pfizer sues Johnson & Johnson, alleging anticompetitive practices to maintain a drug monopoly
Washington Post • Carolyn Y. Johnson
Pfizer sues Johnson & Johnson over Remicade biosimilar
CNBC
Sell Johnson & Johnson because of its 'stretched' valuation: Goldman
CNBC
Johnson & Johnson's Dividend Will Continue To Chug Along, But Likely At A Slower Pace
Seeking Alpha • Accelerating Dividends
State AGs gang up on opioid makers, 41 now in coalition
Seeking Alpha • Douglas W. House
Surgeons lacked caution in use of vaginal mesh implants, doctor admits
The Guardian • Christopher Knaus
 
Recommended for You
Johnson & Johnson
Johnson & Johnson was alerted to risk of asbestos in talc in ’70s, files show.
BloombergJef Feeley
Documents unsealed in suit show traces of carcinogen in mine J&J’s tests going back to 1972 find no traces of asbestos Johnson & Johnson trained its employees to reassure anyone concerned about whether the company’s talcum powder contained asbestos that the cancer-causing...
Share
Economic Policy, Finance
Where To Invest Now
Seeking AlphaNicholas P. Cheer
Summary While I remain cautious on the market as a whole, I continue to be invested in a select group of equities across the globe. Health care is one area I believe will continue to demonstrate above average growth rates and have...
Share
Biotechnology, Cancer
3 Things In Biotech You Should Learn Today: September 22, 2017
Seeking AlphaZach Hartman
Summary Pfizer expands its first immunotherapy approval into Europe. Audentes steps onto the clinical stage in a congenital muscle malady. Janssen and MorphoSys collab now in late-stage investigations for arthritis. Welcome to another edition of "3 Things In Biotech You Should Learn...
Share
Abbott Laboratories, Health Finance
Johnson & Johnson Acquires Sightbox For Contact Lens Subscriptions
Seeking AlphaDonovan Jones
Summary Johnson & Johnson Vision Care has acquired Sightbox for an undisclosed sum. Sightbox has developed a subscription vision care service that connects consumers with eye care professionals and an annual supply of contact lenses. The deal is part of an ongoing...
Share
Finance, Johnson & Johnson
Pfizer sues Johnson & Johnson, alleging anticompetitive practices to maintain a drug monopoly
Washington PostCarolyn Y. Johnson
You’re all set! See all newsletters content from at&t The evolution of on-demand delivery This content is paid for by an advertiser and published by WP BrandStudio. The newsroom was not involved in the creation of this content. Learn more about WP...
Share
Health Insurance, Health Insurance Policy
Pfizer sues Johnson & Johnson over Remicade biosimilar
CNBC
Pfizer filed a lawsuit against Johnson & Johnson, saying their anticompetitive contracts with health insurers prevented biosimilar competition to Remicade.
Share
Finance, Hedge Funds
Sell Johnson & Johnson because of its 'stretched' valuation: Goldman
CNBC
Goldman Sachs lowers its rating for Johnson & Johnson to sell from neutral.
Share
Accounting, Actelion Pharmaceuticals
Johnson & Johnson's Dividend Will Continue To Chug Along, But Likely At A Slower Pace
Seeking AlphaAccelerating Dividends
Summary Johnson & Johnson is a dividend stalwart. The recent dividend raise led me to question whether this was a one-time event or the beginning of lower expectations. My analysis shows that management is fixated on increasing the dividend payout by $0.03...
Share
Johnson & Johnson, McKesson Corp
State AGs gang up on opioid makers, 41 now in coalition
Seeking AlphaDouglas W. House
Realizing a golden opportunity to extract money from corporations, 41 state attorneys general have expanded their investigations into alleged misleading marketing by drug firms aimed at boosting sales of prescription opioid medications and contributing greatly to the opioid addiction crisis. Endo International...
Share
Health Care Industry, Johnson & Johnson
Surgeons lacked caution in use of vaginal mesh implants, doctor admits
The GuardianChristopher Knaus
The corporate giant Johnson & Johnson says it acted “ethically and responsibly” in developing and selling its controversial transvaginal mesh implants, which have left hundreds of Australian women with chronic and debilitating pain. A Senate inquiry is currently examining the impact of...
Share